Close
Chethan Ramamurthy, M.D.
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Chethan Ramamurthy, M.D.
Dr. Chethan Ramamurthy is a graduate of the Baylor College of Medicine in Houston and completed his postgraduate medical training at the University of Pennsylvania and Fox Chase Cancer Center in Philadelphia. His clinical focus is in genitourinary cancers including prostate, kidney, and bladder cancer, as well as cancer genetic risk assessment. His research focus is on developing new strategies for the treatment of genitourinary cancers and understanding the genomic underpinnings of these diseases, with an additional emphasis on reducing cancer care disparities.
Gender
- Male
Languages Spoken
- English
- Spanish
- Kannada
-
Credentials
Credentials
Certifications
- American Board of Internal Medicine
Education
- Medical School: Baylor College of Medicine
- Internship: Hospital of the University of Pennsylvania
- Residency: University of Pennsylvania
- Fellowship: Temple University Hospital
- Locations & Contact
-
Research & Publications
Research & Publications
No Research & Publications
-
Clinical Trials
Clinical Trials
Type of Cancer
Urinary Bladder
ClinicalTrials.gov Identifier
NCT02844816
Principal Investigator
Chethan Ramamurthy M.D.
S1605, Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (CTMS# 18-0014)
This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back (recurrent) and has not responded to treatment (refractory) with Bacillus Calmette-Guerin (BCG). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells…
Type of Cancer
Prostate
ClinicalTrials.gov Identifier
NCT03371719
Principal Investigator
Chethan Ramamurthy M.D.
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer, NRG-GU006 (CTMS# 18-0115)
This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with stage III-IV prostate cancer. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving radiation therapy and…
Type of Cancer
Urothelial Tract/Bladder Cancer
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Chethan Ramamurthy M.D.
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer (CTMS# 19-0019)
ClinicalTrials.gov Identifier
NCT04164082
Principal Investigator
Chethan Ramamurthy M.D.
A031803, Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer CTMS#: 20-0004
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from…
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Chethan Ramamurthy M.D.
PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC